Barclays PLC reduced its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 236,398 shares of the company's stock after selling 4,830 shares during the period. Barclays PLC owned 0.08% of AbCellera Biologics worth $2,338,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of AbCellera Biologics during the 3rd quarter worth approximately $26,000. National Bank of Canada FI grew its position in AbCellera Biologics by 69.3% in the 3rd quarter. National Bank of Canada FI now owns 2,700 shares of the company's stock valued at $27,000 after acquiring an additional 1,105 shares during the last quarter. Worth Asset Management LLC bought a new position in AbCellera Biologics in the 1st quarter valued at $25,000. Banque Cantonale Vaudoise bought a new position in AbCellera Biologics in the 2nd quarter valued at $67,000. Finally, Nisa Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics in the 2nd quarter worth $85,000. 42.19% of the stock is owned by hedge funds and other institutional investors.
Get AbCellera Biologics alerts:Insider Buying and Selling at AbCellera Biologics
In other AbCellera Biologics news, major shareholder Holdings Ltd. Thermopylae bought 85,102 shares of the company's stock in a transaction on Friday, December 16th. The shares were bought at an average price of $10.10 per share, for a total transaction of $859,530.20. Following the transaction, the insider now owns 55,859,493 shares of the company's stock, valued at approximately $564,180,879.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 30.30% of the stock is owned by company insiders.
AbCellera Biologics Price Performance
ABCL opened at $11.01 on Friday. AbCellera Biologics Inc. has a 12 month low of $5.42 and a 12 month high of $14.97. The stock has a market capitalization of $3.15 billion, a price-to-earnings ratio of 13.94 and a beta of -0.16. The business has a fifty day moving average price of $10.64 and a 200 day moving average price of $11.10.AbCellera Biologics (NASDAQ:ABCL – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). AbCellera Biologics had a return on equity of 21.15% and a net margin of 41.17%. The business had revenue of $101.38 million for the quarter, compared to analysts' expectations of $77.19 million. On average, research analysts anticipate that AbCellera Biologics Inc. will post 0.62 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. SVB Leerink decreased their price objective on AbCellera Biologics from $20.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, January 6th. Piper Sandler cut their price objective on AbCellera Biologics from $22.00 to $21.00 in a report on Tuesday, November 1st. The Goldman Sachs Group started coverage on AbCellera Biologics in a report on Thursday, December 15th. They set a "buy" rating and a $30.00 target price on the stock. Finally, Truist Financial assumed coverage on AbCellera Biologics in a report on Wednesday, November 16th. They set a "buy" rating and a $29.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $28.67.
AbCellera Biologics Profile
(Get Rating)
AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
Further Reading
- Get a free copy of the StockNews.com research report on AbCellera Biologics (ABCL)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.